Chronic DiseaseClinical TrialDepressionDiabetesGut Microbiome

Small intestinal bacterial overgrowth: Association with chronic diseases.

Supervisors: Hans Fischer, Walter Fischer

Master of Science Program in Pharmaceutical Microbiology

Department of Medical Biochemistry and Microbiology
Faculty of Medicine
Uppsala University

 

Why this matters for your gut health

The small intestine is far more than a digestive tube — it is a critical interface between your gut bacteria and your immune system, nervous system, and even your brain. When bacteria overgrow in the wrong place, the consequences may reach far beyond bloating and discomfort.

This research matters because it suggests SIBO is not just a gut problem. Bacterial byproducts produced in the small intestine can trigger inflammatory cascades — elevating cytokines like TNF-α and IL-6 — that have been linked to depression, insulin resistance, liver damage, and neurodegeneration. In Parkinson’s disease patients specifically, SIBO was associated with significantly worse motor function, suggesting the gut-brain axis is a real and measurable phenomenon, not just a theory.

For everyday gut health, this means that persistent symptoms like bloating, fatigue, brain fog, unstable blood sugar, or mood disturbances may have a bacterial root in the small intestine — one that standard testing often misses. Gut Clear was formulated precisely to target the bacterial pathways identified in research like this, measuring your TMAO precision load and supporting the microbial balance that protects not just your gut, but your heart, liver, kidneys, and brain.

Summary

SIBO is characterized by an abnormal increase in bacteria within the small intestine, leading to symptoms like bloating, abdominal pain, constipation, and diarrhea. This literature review examined seven clinical and randomized controlled trials (2014–2022) investigating SIBO’s association with IBS, depression, diabetes, chronic liver disease, Parkinson’s disease, restless leg syndrome, and systemic sclerosis. Treatments targeting SIBO — including rifaximin, probiotics, and herbal preparations — generally improved gastrointestinal symptoms and quality of life across most conditions studied. While causal relationships remain to be established, the findings suggest SIBO may be a contributing variable in a broader spectrum of chronic diseases, possibly through inflammatory and neuroimmune gut-brain axis mechanisms.

Key findings

  • Patients with SIBO and depression/diabetes showed significant reductions in anxiety and depression scores, inflammatory cytokines (TNF-α, IL-2), and fasting plasma glucose when treated with lactic acid bacteria alongside standard antidepressant therapy
  • Rifaximin treatment significantly improved gastrointestinal symptoms and quality of life in 57.7% of IBS patients with SIBO
  • Short-term probiotic therapy alleviated SIBO and GI symptoms in chronic liver disease patients, though gut permeability and liver enzyme levels did not significantly improve
  • 25.3% of Parkinson’s disease patients tested positive for SIBO; SIBO-positive PD patients showed worse motor fluctuations and reduced daily activity
  • Rifaximin treatment for restless leg syndrome with SIBO produced moderate but meaningful improvement in RLS symptom scores compared to placebo
  • In systemic sclerosis, the combination of Saccharomyces boulardii and metronidazole eradicated SIBO in 55% of patients and significantly reduced GI symptoms
  • Eradicating SIBO in Parkinson’s patients reduced motor fluctuations, though a 43% SIBO relapse rate was observed at 6 months

Read the full paper
VIEW PDF
Citation

Daabas, A. (2022). Small intestinal bacterial overgrowth: Association with chronic diseases [Master’s thesis, Uppsala University]. Department of Medical Biochemistry and Microbiology, Faculty of Medicine, Uppsala University.

Related Research Papers
n